Celularity
CELU | NASDAQ
$0.62
-$0.01 (-1.60%)
At close: Nov 16, 2026, 4:00 PM ET
$0.62
$0.00 (-0.15%)
After-hours:
Nov 16, 2026, 7:12 PM ET
Celularity Company Profile
Company profile explainedCompany Profile
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
Key Executives
| Name | Position |
|---|---|
| Robert Joseph Hariri | Founder, Chief Executive Officer & Chairman |
| John Sprague | Acting Chief Financial Officer |
| Carlos Ramirez | SVP of Investor Relations |
| David Jakob Lemus | Treasurer |
| Kyle Harold Fletcher | Chief Legal and Strategy Officer & Corporate Secretary |
| Sharmila Koppisetti | Senior Vice President of Clinical Dev. Immunology & Drug Safety |
| Steven N. Gordon | Chief Operating and Administrative Officer & Director |
| Tim Wilk | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 8-K | Current Report |
| Oct 29, 2026 | PRE 14A | Filing |
| Oct 20, 2026 | 10-Q | Quarterly Report |
| Oct 20, 2026 | 10-K/A | [Amend] Annual Report |
| Sep 29, 2026 | 8-K | Current Report |
| Sep 29, 2026 | 10-Q | Quarterly Report |
| Sep 28, 2026 | SC 13D/A | [Amend] Filing |
| Sep 28, 2026 | 8-K | Current Report |
| Sep 25, 2026 | 4 | Filing |
| Sep 25, 2026 | 4 | Filing |
Celularity
| Country | United States |
| IPO Date | Aug 8, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 115 |
| CEO | Robert Joseph Hariri |
Contact Details
170 Park Avenue Florham Park,
New Jersey 07932 United States
Stock Details
| Ticker Symbol | CELU |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001752828 |
| CUSIP Number | 151190204 |
| ISIN Number | US1511902041 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove CELU